Home Newsfeeds Wolfe Research Downgrades Saia to Peer Perform

Wolfe Research Downgrades Saia to Peer Perform

Wolfe Research analyst Scott Group downgrades Saia (NASDAQ:SAIA) from Outperform to Peer Perform.

byBenzinga Newsdesk

November 17, 2022

1 minute read

Wolfe Research analyst Scott Group downgrades Saia (NASDAQ:SAIA) from Outperform to Peer Perform.

Unity Software Rejects Unsolicited Proposal From Applovin

By Anusuya Lahiri

August 15, 1:30 PM

Unity Software Inc (NYSE:U) unanimously rejected the unsolicited proposal from Applovin Corp (NASDAQ:APP) without expecting any superior proposal. Unity reaffirmed its allegiance to ironSource…

APP

Boston Properties Q3 FFO $1.91, Sales $790.52M Beat $762.50M Estimate

By Michael Horton

October 25, 5:49 PM

Boston Properties (NYSE:BXP) reported quarterly earnings of $1.91 per share which beat the analyst consensus estimate of $0.75 by 154.67 percent. This is a 10.4 percent increase over earnings of $1.73 per share from the

BXP

US Stocks Set To Finish First Half Of Year On A High: Why Analyst Sees Bullish Momentum Seeping Into H2

By Shanthi Rexaline

June 30, 6:48 AM

Trading in U.S. index futures point to a positive start in the final session of the second quarter…

CCL

Coeptis Therapeutics Sets Sights on Expanding Cancer and Autoimmune Treatments in 2024

By Benzinga Newsdesk

January 4, 8:38 AM

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave

COEP

Wolfe Research Downgrades Saia to Peer Perform

Related Posts

Unity Software Rejects Unsolicited Proposal From Applovin

Boston Properties Q3 FFO $1.91, Sales $790.52M Beat $762.50M Estimate

US Stocks Set To Finish First Half Of Year On A High: Why Analyst Sees Bullish Momentum Seeping Into H2

Coeptis Therapeutics Sets Sights on Expanding Cancer and Autoimmune Treatments in 2024